These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 22760295

  • 21. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
    Yu F, Lu L, Liu Q, Yu X, Wang L, He E, Zou P, Du L, Sanders RW, Liu S, Jiang S.
    Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
    [Abstract] [Full Text] [Related]

  • 22. Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry.
    He Y, Liu S, Jing W, Lu H, Cai D, Chin DJ, Debnath AK, Kirchhoff F, Jiang S.
    J Biol Chem; 2007 Aug 31; 282(35):25631-9. PubMed ID: 17616522
    [Abstract] [Full Text] [Related]

  • 23. Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.
    Ma X, Tan J, Su M, Li C, Zhang X, Wang C.
    PLoS One; 2014 Aug 31; 9(11):e111923. PubMed ID: 25393106
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
    Korazim O, Sackett K, Shai Y.
    J Mol Biol; 2006 Dec 15; 364(5):1103-17. PubMed ID: 17045292
    [Abstract] [Full Text] [Related]

  • 27. Multimerized CHR-derived peptides as HIV-1 fusion inhibitors.
    Nomura W, Hashimoto C, Suzuki T, Ohashi N, Fujino M, Murakami T, Yamamoto N, Tamamura H.
    Bioorg Med Chem; 2013 Aug 01; 21(15):4452-8. PubMed ID: 23800723
    [Abstract] [Full Text] [Related]

  • 28. A time-resolved fluorescence assay to identify small-molecule inhibitors of HIV-1 fusion.
    Dams G, Van Acker K, Gustin E, Vereycken I, Bunkens L, Holemans P, Smeulders L, Clayton R, Ohagen A, Hertogs K.
    J Biomol Screen; 2007 Sep 01; 12(6):865-74. PubMed ID: 17644771
    [Abstract] [Full Text] [Related]

  • 29. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.
    He Y, Cheng J, Li J, Qi Z, Lu H, Dong M, Jiang S, Dai Q.
    J Virol; 2008 Jul 01; 82(13):6349-58. PubMed ID: 18417584
    [Abstract] [Full Text] [Related]

  • 30. Heteromeric assembled polypeptidic artificial hydrolases with a six-helical bundle scaffold.
    Bai Y, Ling Y, Shi W, Cai L, Jia Q, Jiang S, Liu K.
    Chembiochem; 2011 Nov 25; 12(17):2647-58. PubMed ID: 21957084
    [Abstract] [Full Text] [Related]

  • 31. Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.
    Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y.
    Viruses; 2019 Jul 03; 11(7):. PubMed ID: 31277353
    [Abstract] [Full Text] [Related]

  • 32. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket.
    Chong H, Qiu Z, Su Y, Yang L, He Y.
    AIDS; 2015 Jan 02; 29(1):13-21. PubMed ID: 25562490
    [Abstract] [Full Text] [Related]

  • 33. Single-chain protein mimetics of the N-terminal heptad-repeat region of gp41 with potential as anti-HIV-1 drugs.
    Crespillo S, Cámara-Artigas A, Casares S, Morel B, Cobos ES, Mateo PL, Mouz N, Martin CE, Roger MG, El Habib R, Su B, Moog C, Conejero-Lara F.
    Proc Natl Acad Sci U S A; 2014 Dec 23; 111(51):18207-12. PubMed ID: 25489108
    [Abstract] [Full Text] [Related]

  • 34. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD.
    AIDS Rev; 2003 Dec 23; 5(4):214-21. PubMed ID: 15012000
    [Abstract] [Full Text] [Related]

  • 35. Probing Vulnerability of the gp41 C-Terminal Heptad Repeat as Target for Miniprotein HIV Inhibitors.
    Jurado S, Moog C, Cano-Muñoz M, Schmidt S, Laumond G, Ruocco V, Standoli S, Polo-Megías D, Conejero-Lara F, Morel B.
    J Mol Biol; 2020 Sep 18; 432(20):5577-5592. PubMed ID: 32822695
    [Abstract] [Full Text] [Related]

  • 36. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation.
    Dwyer JJ, Hasan A, Wilson KL, White JM, Matthews TJ, Delmedico MK.
    Biochemistry; 2003 May 06; 42(17):4945-53. PubMed ID: 12718536
    [Abstract] [Full Text] [Related]

  • 37. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
    Li W, Lu L, Li W, Jiang S.
    Expert Opin Ther Pat; 2017 Jun 06; 27(6):707-719. PubMed ID: 28076686
    [Abstract] [Full Text] [Related]

  • 38. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
    Chong H, Yao X, Qiu Z, Sun J, Qiao Y, Zhang M, Wang M, Cui S, He Y.
    J Antimicrob Chemother; 2014 Oct 06; 69(10):2759-69. PubMed ID: 24908047
    [Abstract] [Full Text] [Related]

  • 39. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
    Mzoughi O, Gaston F, Granados GC, Lakhdar-Ghazal F, Giralt E, Bahraoui E.
    ChemMedChem; 2010 Nov 08; 5(11):1907-18. PubMed ID: 20922745
    [Abstract] [Full Text] [Related]

  • 40. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds.
    Liu S, Wu S, Jiang S.
    Curr Pharm Des; 2007 Nov 08; 13(2):143-62. PubMed ID: 17269924
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.